CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 55 enrolled
Drug / intervention
Heme Iron Polypeptide (Proferrin) +1 moredrug
Likely dose
Heme Iron Polypeptide (Proferrin) 11mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00318812
NCT00318812Phase 3Completed
CompareCT.gov

Heme Iron Polypeptide for the Treatment of Iron Deficiency Anemia in Pre-Dialysis Patients: A Pilot Randomized Controlled Study

Ottawa Hospital Research Institute·interventional·Posted Apr 27, 2006·Updated May 10, 2016

In Brief

A Phase 3 clinical trial evaluating Heme Iron Polypeptide (Proferrin) and Iron sucrose (Venofer) for Anemia and Renal Failure. Completed, enrolled 55 participants across 1 site.

Detailed Summary

The purpose of this study is to determine if oral Heme Iron Polypeptide is as effective as intravenous (IV) iron sucrose in the treatment of iron-deficiency anemia for patients with chronic kidney disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia, Renal Failure
CountriesCanada
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 27, 2006
Enrollment StartMay 1, 2007
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 20.2 years ago

Interventions

Heme Iron Polypeptide (Proferrin)drug

Heme iron polypeptide 11mg po tid for 6 months

Iron sucrose (Venofer)drug

Iron sucrose infusion IV q month x 6 months